How to Treat Precancerous Cells in the Stomach?

Treatment for precancerous cells in the stomach depends on how far along the process has advanced, because “precancerous” is not a single condition. The stomach lining can progress through several distinct stages before cancer develops, and the right intervention at one stage may be unnecessary or insufficient at another. For most people, the journey starts with treating the underlying cause, usually a bacterial infection, and escalates to endoscopic procedures or closer surveillance only when the changes become more worrisome. Understanding where you fall on that spectrum is the first step toward knowing what treatment looks like for you.

The Precancerous Cascade and Why Stage Matters

Stomach cancer does not appear overnight. It is typically preceded by a stepwise series of changes to the stomach lining that can take years or decades to unfold. The sequence, sometimes called the Correa cascade after the researcher who described it, starts with chronic inflammation of the stomach lining. If that inflammation persists, glands in the stomach wall begin to disappear, a condition called atrophic gastritis. From there, the lining can undergo intestinal metaplasia, where normal stomach cells are gradually replaced by cells that resemble those found in the intestine. The final precancerous stage is dysplasia, first low-grade, then high-grade, which represents genuinely abnormal cell growth and sits right at the threshold of cancer.¹

Not every step carries the same risk. Intestinal metaplasia itself comes in subtypes. The “incomplete” type, where the replacement cells look less like normal intestinal tissue, carries roughly five times the cancer risk compared with the “complete” type.² And among the incomplete subtypes, the most disorganized form (type III) carries the highest risk of all, with one meta-analysis estimating about a sixfold increase in cancer or dysplasia compared with the milder subtypes.³ This is why biopsies and accurate staging are so important: they determine whether your doctor recommends watchful waiting, active treatment, or something in between.

Treating the Root Cause First

The single most important treatment for early precancerous changes in the stomach is getting rid of Helicobacter pylori, the bacterium that drives the majority of cases. H. pylori infection causes the chronic inflammation that kicks off the entire cascade, and eradicating it with antibiotics can slow or even partially reverse the damage. A systematic review and meta-analysis found that wiping out H. pylori significantly prevented the progression of precancerous lesions overall and also improved both atrophic gastritis and intestinal metaplasia compared with no treatment.⁴

The catch is that the benefit shrinks the further the damage has progressed. Eradication works best at the inflammation and early atrophy stages. Once extensive intestinal metaplasia or dysplasia has set in, clearing the infection still helps reduce ongoing damage, but it is less likely to reverse the changes already present. That said, treatment is still recommended regardless of stage because removing the ongoing inflammatory trigger slows progression and lowers the probability of cancer developing down the line.

H. pylori is not the only driver, though. Bile reflux, where digestive bile flows backward into the stomach, is an independent risk factor for both precancerous lesions and stomach cancer itself.⁵ The severity of bile reflux appears to matter: higher-grade reflux has been linked to greater progression of stomach mucosal disease.⁶ Autoimmune gastritis, a less common condition where the immune system attacks the stomach lining without H. pylori involvement, can also lead to severe atrophy and carries its own risk, compounded by factors like low stomach acid, elevated gastrin levels, bile reflux, smoking, and family history.⁷

Risk Staging and Surveillance

After biopsies confirm precancerous changes, your doctor will classify the severity using a staging system. Two widely used scoring methods assess how much of the stomach is affected by atrophy and intestinal metaplasia, mapping the extent and severity across different stomach regions. These staging scores are not abstract academic exercises; they directly predict your cancer risk and determine how closely you need to be watched.

The numbers are striking. Patients with advanced-stage atrophy or intestinal metaplasia (stages III–IV in either scoring system) face dramatically higher cancer risk compared with those in the earlier stages. One systematic review of prospective studies found that advanced atrophy staging was associated with roughly a 32-fold increased risk of stomach cancer, and advanced intestinal metaplasia staging with about a 12-fold increase.⁸ Even moderate-stage intestinal metaplasia carried about a tenfold increase in cancer risk compared with the lowest stages.⁸ Another meta-analysis confirmed that these advanced staging categories are reliably associated with gastric cancer.⁹

Current guidelines from gastroenterology societies generally recommend endoscopic surveillance every three years for patients with extensive atrophic gastritis or intestinal metaplasia affecting multiple regions of the stomach. British guidelines specify that surveillance should be offered when both the antrum and body are involved, but that patients with changes limited to the antrum alone do not necessarily need surveillance unless they have additional risk factors like a strong family history or persistent H. pylori infection.¹⁰ American Gastroenterological Association guidance similarly calls for risk stratification in everyone with confirmed atrophy or intestinal metaplasia, with three-year surveillance intervals for those at higher risk, and potentially shorter intervals when multiple risk factors pile up.¹¹

Endoscopic Resection for Dysplasia and Early Cancer

When precancerous changes progress to dysplasia, especially high-grade dysplasia, the treatment shifts from “monitor and manage risk factors” to “remove the abnormal tissue.” This is where endoscopic procedures come in. The two primary techniques are endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Both are performed through an endoscope, the flexible tube that is passed through the mouth into the stomach, avoiding the need for open surgery.

EMR strips away the abnormal mucosal layer, often in pieces. ESD is a more technically demanding procedure that carefully dissects beneath the lesion, removing it in one intact piece regardless of size. The tradeoff is well-documented: ESD takes longer and carries a higher perforation risk, but it achieves much higher rates of complete removal and dramatically lower recurrence. A meta-analysis found that ESD had about a ten-times higher rate of removing lesions in one piece compared with EMR and roughly a six-times higher rate of complete histological removal. In turn, recurrence after ESD was about 90% lower.¹² Data on endoscopic resection are particularly robust in Japan and Korea, where these techniques have been refined over decades with high success rates and relatively low complication rates.¹³

A cost-effectiveness analysis found that for individuals with dysplasia, EMR with annual surveillance afterward was the optimal strategy across population subgroups. For people with intestinal metaplasia coming from countries where stomach cancer rates are high, EMR combined with surveillance every five to ten years could also be cost-effective.¹⁴

Complications and How They Are Managed

Bleeding and perforation are the two main complications of endoscopic resection procedures.¹⁵ Bleeding can occur during the procedure or be delayed by days. Perforation, a small hole through the stomach wall, is more common with ESD because of the deeper dissection involved. Most of these complications can be managed endoscopically, through cauterization for bleeding or clip closure for perforations, without requiring surgery.

One systematic review found that using prophylactic clips to close the wound left by resection cut the odds of delayed bleeding by about 65% and reduced perforation risk by more than half. The protective benefit was especially strong for larger lesions and for procedures done in the duodenum, and clip closure was more protective after ESD than after EMR.¹⁶ Your endoscopist will weigh the size and location of the lesion to decide whether preventive clipping is warranted.

Ablation Therapies for Flat or Widespread Lesions

Not every precancerous change shows up as a distinct, removable lump. Intestinal metaplasia in particular can spread diffusely across the stomach lining, making targeted resection impractical. In these cases, ablation techniques that destroy the abnormal surface layer are being used with increasing frequency.

Argon plasma coagulation (APC) uses a jet of ionized argon gas to burn away superficial tissue. Hybrid APC, a newer variant, injects fluid beneath the lining before ablation, creating a protective cushion that reduces the risk of deep injury. A case report documented its use for diffuse intestinal metaplasia with good results.¹⁷ Radiofrequency ablation (RFA), already well-established for treating precancerous tissue in the esophagus, is also being applied in the stomach. A large retrospective study comparing the two found that both RFA and APC are safe and effective for low-grade precancerous changes, but they suit different types of lesions: RFA works better for flat, widespread areas, while APC is better suited for smaller spots, particularly those with slight surface irregularities.¹⁸

It is worth noting that APC, while accessible and inexpensive, has a higher local recurrence rate when used for low-grade dysplasia. A multicenter study found that recurrence occurred in about 4% of patients treated with APC over a median follow-up of roughly 29 months, compared with 0.2% after EMR and 0.8% after ESD.¹⁹ The recurrence gap makes sense: ablation destroys tissue without providing a specimen, so there is no way to confirm the abnormal cells were fully eliminated. Resection provides a tissue sample that a pathologist can examine to verify clean margins.

Lifestyle Factors That Speed or Slow the Process

Smoking is one of the clearest modifiable risk factors for progression. A study in a high-risk population found that cigarette smoking nearly doubled the risk of transitioning from earlier precancerous stages to dysplasia. Smoking also explained almost the entire 55% gap in dysplasia prevalence between men and women in that population. Family history of stomach cancer and blood type A were also associated with higher progression risk, while dietary factors showed weaker and less consistent associations.²⁰

Diet is harder to pin down from a treatment perspective. High salt intake, processed meats, and low fruit and vegetable consumption are associated with stomach cancer risk in population studies, but no dietary intervention has been proven in randomized trials to reverse intestinal metaplasia or dysplasia. That does not mean diet is irrelevant; it means the evidence supports general healthy eating as part of overall risk reduction rather than a specific food-based “treatment” for precancerous cells.

Could Anti-Inflammatory Drugs Help?

There has been longstanding interest in whether nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, could prevent stomach cancer by suppressing a key enzyme involved in inflammation and tumor growth. Population studies have found that regular NSAID use is associated with a reduced risk of stomach cancer.²¹ Lab studies suggest the effect works through both inflammation-dependent and independent pathways, including triggering cell death in abnormal cells and limiting blood vessel growth in tumors.²²

The problem is that NSAIDs can also damage the stomach lining, causing ulcers and bleeding, which makes recommending them as a stomach-cancer prevention strategy a hard sell. Selective COX-2 inhibitors were developed to reduce that gastrointestinal toxicity, but fundamental questions about the right dose, the right treatment duration, and long-term safety remain unresolved.²³ At this point, no major guideline recommends NSAIDs specifically to treat or prevent precancerous stomach changes. This is an area where the research is suggestive but not yet actionable for most patients.

How Precancerous Changes Are Detected

Treatment decisions rest on accurate detection, and standard white-light endoscopy often misses early precancerous changes. Narrow-band imaging (NBI), a technology that uses filtered light to enhance the visibility of mucosal surface patterns and blood vessels, substantially improves detection. A meta-analysis found that NBI combined with magnification endoscopy had per-lesion sensitivity of about 84% and specificity of about 93% for detecting intestinal metaplasia.²⁴ Another study found that the characteristic light-blue crest pattern seen under magnification had an accuracy of 93% for identifying intestinal metaplasia.²⁵

Artificial intelligence is starting to enter this space as well. A multicenter study tested a computer-aided detection system on endoscopic images and found it matched expert endoscopists in identifying both atrophic gastritis and intestinal metaplasia, with accuracy hovering around 86–90%. The AI system outperformed non-expert endoscopists, which matters because in practice many endoscopies are not performed by subspecialists with extensive experience reading these subtle mucosal patterns.²⁶ These tools are not yet standard, but they suggest that detection will improve significantly in the coming years, catching cases earlier and guiding biopsies more precisely.

The Changing Stomach Microbiome

Beyond H. pylori, the broader community of bacteria living in the stomach appears to shift as precancerous changes progress. Research has found that bacterial diversity in the stomach lining decreases as gastritis advances, with H. pylori being the main driver of that drop in diversity. But other bacteria also change: certain genera become more prominent across different stages of the precancerous cascade, and at least one genus has been linked specifically to the development of early neoplasia.²⁷

This is early-stage science, but it opens up an intriguing possibility: could restoring a healthier microbial balance in the stomach slow or prevent progression? Some researchers are investigating whether probiotics or microbiome-targeted therapies could complement H. pylori eradication, but there are no proven treatments based on microbiome manipulation yet. The research is primarily helping scientists understand why some people with the same H. pylori strain progress to cancer while others do not.

When Does Surgery Enter the Picture?

For the vast majority of people with precancerous stomach changes, surgery is not on the table. Endoscopic techniques handle most dysplastic lesions effectively. Surgery becomes relevant in two specific situations: when a lesion cannot be completely removed endoscopically, typically because it is too large, has invaded too deeply, or sits in a location that makes endoscopic access difficult, and when pathology review after an endoscopic resection reveals that cancer has already developed beneath what looked like a precancerous surface.

There is also a rare scenario involving hereditary diffuse gastric cancer, a genetic condition caused by mutations in the CDH1 gene. People who carry this mutation face an extremely high lifetime risk of developing an aggressive form of stomach cancer, and the precancerous changes that precede it are notoriously difficult to detect with standard endoscopy because they grow beneath the surface. For these individuals, preventive removal of the entire stomach (total gastrectomy) is sometimes recommended. This is a major decision with lifelong consequences for digestion, nutrition, and quality of life, and the psychological impact is significant, affecting emotional functioning, body image, relationship with food, and anxiety.²⁸ It is a decision made in consultation with genetics specialists, surgeons, and often psychologists, not something any doctor takes lightly.

Cost-Effectiveness and Screening in Different Populations

Whether intensive surveillance of precancerous lesions makes economic sense depends heavily on how likely a person is to develop cancer. In populations where stomach cancer is common, such as in East Asia, regular surveillance of people with intestinal metaplasia can be justified. In lower-risk populations, the math is less clear. Modeling studies have found that the cost-effectiveness of endoscopic surveillance depends on assumptions about how fast disease progresses, and in very low-risk scenarios, even a single follow-up endoscopy may not be cost-effective.²⁹

This creates a real tension for patients in countries like the United States, where stomach cancer is relatively uncommon overall but significantly more common in certain immigrant communities, particularly those from East Asia and Latin America. Personalized risk assessment, accounting for ethnicity, immigration background, family history, H. pylori status, and the extent and subtype of any precancerous changes, is becoming the standard approach rather than one-size-fits-all surveillance schedules. That personalization is also why getting an accurate biopsy protocol during your initial endoscopy matters so much: the biopsies determine your stage, and your stage determines everything that follows.